NYHA Functional Class III Pulmonary arterial hypertension

Pulmonary arterial hypertension (PAH) is a serious, life-threatening condition characterized by increased pressure in the pulmonary arteries, which are the blood vessels that supply the lungs. When PAH is severe, it can lead to heart failure and even death. People with PAH are subject to classification by the New York Heart Association (NYHA) functional class. NYHA Functional Class III (FC III) indicates that the person has an advanced form of PAH with marked limitations of activity.

Symptoms of NYHA Functional Class III Pulmonary arterial hypertension

The symptoms of PAH associated with FC III are more severe than in earlier stages. People with FC III generally experience difficulty breathing on exertion, chest pain upon exertion, a decrease in exercise endurance, and often have significant fatigue and “shortness of breath” (dyspnea) at rest. In addition, they may experience syncope (fainting) during exertion, edema (swelling) in the lower extremities, and small-capacity lungs.

Treatments for NYHA Functional Class III Pulmonary arterial hypertension

The primary goals of treatment for PAH are to reduce symptoms, improve quality of life, and prevent progression of the disease. Treatment for FC III specifically involves various medication regimens, supportive treatments, and lifestyle changes. Some medications, such as phosphodiesterase-5 inhibitors and prostacyclin analogs, can help reduce pulmonary vascular resistance and improve exercise capacity. Additionally, supportive treatments such as supplemental oxygen and diuretics can help reduce edema. Additionally, lifestyle changes may include avoiding overexertion, avoiding exposure to dust, smoke, and other allergens, getting an influenza vaccination annually, and quitting smoking.

Outlook for NYHA Functional Class III Pulmonary arterial hypertension

People with FC III PAH have a poor prognosis; they have a significantly higher mortality rate than other PAH patients in earlier stages. Despite this, treatment options such as new medications and supportive treatments can prolong and improve quality of life. Early diagnosis and appropriate treatment can greatly improve a patient's prognosis, and research into new treatments is ongoing.